Minor
Suspected
설명
Azithromycin is a weak CYP3A4 inhibitor that can modestly raise loratadine plasma levels; the clinical impact is minimal given loratadine's wide therapeutic index and low cardiac risk.
기전
Azithromycin inhibits CYP3A4 to a minor degree, reducing hepatic metabolism of loratadine; azithromycin itself carries a small QT-prolonging potential, creating a theoretical additive cardiac risk.
임상적 중요성
No significant QT changes or adverse events are expected at standard doses in patients without underlying cardiac risk factors.
관리 방법
No dose adjustment required; exercise caution in patients with QT prolongation risk factors or electrolyte abnormalities.